Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which patients were dosed every 3 weeks. We hypothesized that dose intensification of ONC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Wagner, Jessica, Kline, C. Leah, Zhou, Lanlan, Campbell, Kerry S., MacFarlane, Alexander W., Olszanski, Anthony J., Cai, Kathy Q., Hensley, Harvey H., Ross, Eric A., Ralff, Marie D., Zloza, Andrew, Chesson, Charles B., Newman, Jenna H., Kaufman, Howard, Bertino, Joseph, Stein, Mark, El-Deiry, Wafik S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983321/
https://ncbi.nlm.nih.gov/pubmed/29533922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96711
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados